Last updated: February 25, 2026
What is NDC 00009-3073?
NDC 00009-3073 corresponds to the drug Hyaluronic Acid, Sodium Hyaluronate, used primarily in ophthalmic injections for the treatment of osteoarthritis of the knee. It is a biosimilar or generic product based on its NDC structure, which indicates a non-branded and potentially lower-cost alternative.
Market Landscape
Current Market Size
- The U.S. osteoarthritis intra-articular injection market was valued at approximately $1.2 billion in 2022.
- Hyaluronic acid products hold around 65-70% of this market, equating to roughly $780 million.
- The market has experienced a compound annual growth rate (CAGR) of 4.5% from 2018 to 2022.
Key Competitors
| Brand Name |
Type |
Price Range (per injection) |
Market Share (2022) |
Notes |
| Euflexxa |
Branded |
$600–$700 |
25% |
Authorised for knee osteoarthritis |
| Orthovisc |
Branded |
$650–$750 |
20% |
Widely prescribed |
| Gel-One |
Branded |
$550–$650 |
15% |
Cost-effective alternative |
| Hyalgan |
Generic |
$200–$300 |
12% |
Biosimilar, lower cost, used more broadly |
| NDC 00009-3073 |
Generic/Biosimilar |
Estimated $150–$250 |
Under 10% initially |
Possibly gaining market share |
Regulatory Status
- No FDA approval has been indicated publicly for NDC 00009-3073 as a specific biosimilar or generic.
- Likely in the development or post-approval phase, targeting markets where biosimilar uptake is growing.
Market Entry Barriers
- Regulatory hurdles: Biosimilar approvals in the U.S. require comprehensive comparability studies.
- Market incumbency: Established branded products hold significant prescriber loyalty.
- Pricing dynamics: Payers favor lower-cost biosimilars to reduce costs.
Price Projection Analysis
Factors Influencing Price
- Regulatory approval timeframe: If NDC 00009-3073 gains approval by 2025, prices could decrease owing to increased competition.
- Market penetration speed: Biosimilars cost 30-50% less than branded counterparts initially.
- Reimbursement policies: Insurance coverage favors biosimilars, pushing prices down.
Short-Term (1-2 Years)
- Price range: $150–$250 per injection.
- Market share: Limited, estimating less than 5% due to ongoing regulatory review, with potential for rapid increase post-approval.
Medium-Term (3-5 Years)
- Price range: $120–$200.
- Market share: Likely to reach 15–20%, driven by payer preference and physician acceptance.
- Market penetration: Pressure on branded products will intensify, leading to further price reductions.
Long-Term (6+ Years)
- Price range: $100–$180.
- Market share: Potentially surpassing 30%, depending on biosimilar acceptance and formulary inclusion.
- Key driver: Increasing adoption in outpatient clinics and bundled payment models.
Pricing Benchmarks Based on Similar Products
| Product |
Launch Price (Approximate) |
Year 5 Price |
Max Market Share |
Comments |
| Zarxio (biosimilar filgrastim) |
$700 (initial) |
$150–$200 |
35% |
Rapid uptake post-approval in oncology |
| Humira biosimilar |
$800 (initial) |
$400–$600 |
20% |
Slower uptake due to brand loyalty |
| Eylea (lucentis biosimilar) |
$800 |
$300–$400 |
25% |
Ophthalmology market trends |
Trends and Considerations
- Market expansion: Biosimilars are entering orthopedics and ophthalmology at increasing rates.
- Reimbursement landscape: Medicare and private insurers are incentivizing biosimilar use.
- Physician adaptation: Reliance on clinical efficacy rather than brand loyalty accelerates biosimilar adoption.
Risks and Opportunities
- Risks: Slow regulatory approval, patent disputes, prescriber resistance.
- Opportunities: Early market entry, strategic pricing, partnerships with payers.
Key Takeaways
- The current market for intra-articular hyaluronic acid is approximately $780 million in 2022, with biosimilar/generic segments steadily gaining ground.
- Price projections for NDC 00009-3073 suggest an initial price of $150–$250, decreasing to $100–$180 over six years.
- Market share growth depends on approval timing, competitive dynamics, and payer policies.
- Competitive advantage hinges on cost, efficacy, and market access strategies.
FAQs
1. When could NDC 00009-3073 reach the U.S. market?
Based on typical biosimilar regulatory timelines, approval could occur within 2–4 years, contingent on successful clinical and chemistry, manufacturing, and controls (CMC) data submission.
2. How does biosimilar adoption impact pricing?
Biosimilar entry generally reduces prices by 30–50% compared to branded products, accelerating as market acceptance grows.
3. What are the main barriers to market penetration?
Physician inertia, patent exclusivities, regulatory hurdles, and formulary preferences pose primary challenges.
4. What is the competitive landscape for biosimilars in osteoarthritis treatments?
Multiple biosimilars and generics are emerging, with market growth driven by cost savings and increased payer support for biosimilar prescribing.
5. How will reimbursement policies influence prices?
Incentives favor lower-cost biosimilars, leading to pressure on pricing and potential discounts to secure formulary placement.
References
-
MarketWatch. (2022). Osteoarthritis drugs market size and forecast. [Data File]
-
IQVIA. (2022). Biologic & Biosimilar Report. [Data File]
-
FDA. (2022). Biosimilar Development and Approval. [Official Guidance]
-
EvaluatePharma. (2022). Oncology biosimilars market analysis. [Market Report]
-
CMS. (2023). Reimbursement policies for biosimilars. [Policy Document]
